SCHEMBL4314653

SCHEMBL4314653

Cc1nc(-c2cccs2)c(Cl)cc1C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.47
PLAU P00749 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
IKBKB O14920 1/20 0.41
MAPT P10636 2/20 0.40
GAA P10253 1/20 0.40
THRB P10828 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
NPC1 O15118 2/20 0.40
RPS6KB2 Q9UBS0 2/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CDC7 O00311 1/20 0.40
ALDH1A1 P00352 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4341036 0.87 KDM4E (0.50) KDM4EPLAUMEN1KMT2AIKBKB
SCHEMBL21543187 0.73 GRM2 (0.46) NPC1HSD17B10CDC7ADORA2ARAB9A
SCHEMBL28342390 0.72 KDM4E (0.56) KDM4EMEN1KMT2AIKBKBMAPT
SCHEMBL25665406 0.71 POLB (0.46) KDM4EGAACA12CA1CA2
SCHEMBL2454771 0.70 KMT2A (0.41) KDM4EMEN1KMT2AIKBKBMAPT
SCHEMBL2454769 0.70 KMT2A (0.41) KDM4EMEN1KMT2AIKBKBMAPT
SCHEMBL31661920 0.69 IKBKB (0.55) KDM4EPLAUMEN1KMT2AIKBKB
SCHEMBL7503112 0.69 KDM4E (0.40) KDM4EPLAUIKBKBMAPTGAA
SCHEMBL3831301 0.68 MEN1 (0.45) KDM4EMEN1KMT2AMAPTGAA
SCHEMBL10406074 0.68 PARP1 (0.46) KDM4EPLAUMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084470-B2 Substituted nicotinamide compounds and uses thereof GRUENENTHAL GMBH (DE) 2011-12-27 US disclosed
US-20090076086-A1 SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF GRUENENTHAL GMBH (DE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076086-A1 SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF NNT, NAMPT, NADK KDM4E 2156/4885PLAU 611/4885MEN1 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.